Canadian medical device company Flosonics Medical has announced the use of its wearable ultrasound device, FloPatch, in two critical care units at St Michael’s Hospital in Canada.
The wearable Doppler ultrasound patch, which has received clearance from both Health Canada and the US Food and Drug Administration (FDA), is designed to facilitate real-time blood-flow assessments.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
This will aid in the fluid resuscitation of patients who are critically ill, including those suffering from sepsis and septic shock.
Sepsis is the third most common cause of death in US hospitals, affecting an estimated 1.7 million individuals annually, as reported by the Centers for Disease Control and Prevention (CDC).
When placed on the patient’s neck over the carotid artery, FloPatch begins transmitting blood flow data for each heartbeat instantly.
This information is then sent wirelessly to a secure iOS application used by healthcare providers.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe application displays real-time Doppler data and also employs advanced analytics to distil each heartbeat into crucial metrics.
Such detailed data is vital for making informed, timely decisions at the bedside, particularly in complex and urgent medical situations like sepsis management.
St Michael’s intensivist and the University of Toronto’s Department of Medicine and Interdepartmental Division of Critical Care Medicine (IDCCM) associate professor Alberto Goffi said: “Our critical care teams are always looking for ways to further improve their capabilities and efficiency and ultimately drive greater patient safety.”
In March this year, the company secured $20m in a Series C funding round led by New Leaf Venture Partners, with contributions from existing investors such as Arboretum Ventures, Genesys Capital, and iGan Partners.
The funds are earmarked for supporting its continued innovation, driving market adoption of FloPatch, and expanding its indications for use.
The company’s goal is to meet the increasing demand for wearable AI-assisted sensors that enhance patient management both in and out of hospital settings.
In September 2023, Riverside University Health System in California announced the deployment of FloPatch for fluid management in sepsis.
